{"id":68480,"date":"2026-08-22T16:28:25","date_gmt":"2026-08-22T16:28:25","guid":{"rendered":"https:\/\/www.europesays.com\/france\/68480\/"},"modified":"2026-08-22T16:28:25","modified_gmt":"2026-08-22T16:28:25","slug":"sanofi-survey-reveals-diabetes-misconceptions-and-screening-gaps","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/france\/68480\/","title":{"rendered":"Sanofi survey reveals diabetes misconceptions and screening gaps"},"content":{"rendered":"<p dir=\"ltr\">Widespread misconceptions about Type 1 diabetes\u00a0<a href=\"https:\/\/www.prnewswire.com\/news-releases\/new-survey-highlights-awareness-gaps-among-type-1-diabetes-families-that-can-create-barriers-to-action-302828805.html\" rel=\"nofollow noopener\" target=\"_blank\">could be<\/a> contributing to a reluctance to get screened for the autoimmune disease, according to a survey Sanofi commissioned.<\/p>\n<p dir=\"ltr\">Working with the nonprofit Beyond Type 1, Sanofi tasked Ipsos with surveying U.S. adults who are at risk of developing Type 1 diabetes and caregivers for at-risk children. The collaborators augmented data from the 1,000-person survey with insights from interviews of 511 adults and caregivers in California, Florida, Georgia, Massachusetts, New York and Texas.<\/p>\n<p dir=\"ltr\">Almost two-thirds of respondents said Type 1 diabetes is primarily diagnosed in children, despite adults\u00a0<a href=\"https:\/\/diabetesjournals.org\/care\/article\/44\/11\/2449\/138477\/Adult-Onset-Type-1-Diabetes-Current-Understanding\" rel=\"nofollow noopener\" target=\"_blank\">accounting for<\/a> more than half of new cases. One-fifth of respondents said autoantibody screening isn\u2019t necessary for adults.\u00a0<\/p>\n<p dir=\"ltr\">Limited awareness of adult-onset Type 1 diabetes is one of several barriers to screening observed in the survey. The survey found a disconnect between the proportion of people concerned about their or their child\u2019s Type 1 diabetes risk\u201482%\u2014and the number planning to get screened. When asked about the next six months, 46% of respondents said they either won\u2019t get screened or are undecided whether to do so.<\/p>\n<p dir=\"ltr\">The survey found 85% of respondents felt more likely to screen once they learned that they were at a heightened risk of developing the disease. Respondents named a doctor\u2019s recommendation and learning more about the screening process as the top two motivators for getting tested.\u00a0\u00a0<\/p>\n<p dir=\"ltr\">Sanofi\u00a0<a href=\"https:\/\/www.fiercepharma.com\/pharma\/once-fda-pathway-speed-its-approval-sanfoi-gains-late-expansion-tzield\" rel=\"nofollow noopener\" target=\"_blank\">received<\/a> an expanded FDA label for Type 1 diabetes treatment Tzield last month. The drug, which is used to delay disease progression, is part of a portfolio of Type 1 diabetes drugs that includes insulin products such as Toujeo. Sanofi\u00a0<a href=\"https:\/\/www.sanofi.com\/assets\/dotcom\/pressreleases\/2026\/2026-04-23-05-30-00-3279572_EN.pdf\" rel=\"nofollow noopener\" target=\"_blank\">reported<\/a> (PDF) Tzield sales of 14 million euros ($16 million) in the first quarter.<\/p>\n<p dir=\"ltr\">The survey\u2019s focus on screening continues Sanofi\u2019s interest in the topic. Last year, the drugmaker\u00a0<a href=\"https:\/\/www.fiercepharma.com\/marketing\/sanofi-signs-chrissy-teigen-diabetes-screening-campaign\" rel=\"nofollow noopener\" target=\"_blank\">signed up<\/a> model Chrissy Teigen for a campaign to encourage people to screen early for Type 1 diabetes. Teigen\u2019s 6-year-old son, Miles, was hospitalized with complications of the autoimmune disease.\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"Widespread misconceptions about Type 1 diabetes\u00a0could be contributing to a reluctance to get screened for the autoimmune disease,&hellip;\n","protected":false},"author":2,"featured_media":37349,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12983],"tags":[24202,26153,1872,22749,13012,42188,25080],"class_list":["post-68480","post","type-post","status-publish","format-standard","has-post-thumbnail","category-sanofi","tag-autoimmune-disease","tag-fierce-pharma-homepage","tag-marketing","tag-pharma","tag-sanofi","tag-screening","tag-type-1-diabetes"],"_links":{"self":[{"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/posts\/68480","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/comments?post=68480"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/posts\/68480\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/media\/37349"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/media?parent=68480"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/categories?post=68480"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/tags?post=68480"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}